News

Technology News

Eiger BioPharma Bags Venture Capital Debt

Tuesday, November 24, 2015 5:04:00 AM PDT | VentureDeal
   Palo Alto, California  --  Eiger BioPharmaceuticals has received $6 million in new venture capital debt funding, according to an SEC regulatory filing.

Eiger is discovering and developing new antiviral agents against novel targets in the treatment of hepatitis.

The company also recently announced a merger with Celladon and an equity commitment of $39.5 million for the combined company.

Investors in the debt financing were not disclosed, nor was how the company intends to use the proceeds.

CEO David Cory has been with the firm since January 2009.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1